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Abstract Purpose: To analyze
trends in incidence and mortality of
candidemia in intensive care units
(ICUs) vs. non-ICU hospitalized
patients and to determine risk factors
for infection by specific species and
for death. Methods: Active hospital-
based surveillance program of inci-
dent episodes of candidemia due to
common species in 24 tertiary care
hospitals in the Paris area, France
between October 2002 and September
2010. Results: Among 2,507 adult
cases included, 2,571 Candida iso-
lates were collected and species were
C. albicans (56 %), C. glabrata
(18.6 %), C. parapsilosis (11.5 %),
C. tropicalis (9.3 %), C. krusei
(2.9 %), and C. kefyr (1.8 %).
Candidemia occurred in ICU in 1,206
patients (48.1 %). When comparing
ICU vs. non-ICU patients, the former
had significantly more frequent sur-
gery during the past 30 days, were
more often preexposed to fluconazole
and treated with echinocandin, and
were less frequently infected with
C. parapsilosis. Risk factors and age
remained unchanged during the study
period. A significant increased inci-
dence in the overall population and
ICU was found. The odds of being
infected with a given species in ICU
was influenced by risk factors and
preexposure to fluconazole and ca-
spofungin. Echinocandins initial
therapy increased over time in ICU
(4.6 % first year of study, to 48.5 %
last year of study, p \ 0.0001). ICU
patients had a higher day-30 death
rate than non-ICU patients (odds ratio
[OR] 2.12; 95 % confidence interval
[CI] 1.66–2.72; p \ 0.0001). The
day-30 and early (\day 8) death rates
increased over time in ICU (from
41.5 % the first to 56.9 % the last
year of study (p = 0.001) and
28.7–38.8 % (p = 0.0292), respec-
tively). Independent risk factors for
day-30 death in ICU were age, arte-
rial catheter, Candida species,
preexposure to caspofungin, and lack
of antifungal therapy at the time of
blood cultures results (p \ 0.05).
Conclusions: The availability of
new antifungals and the publication
of numerous guidelines did not
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prevent an increase of candidemia
and death in ICU patients in the Paris
area.
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Introduction
Candidemia currently represents up to 5.6–10 % of nos-
ocomial bloodstream infections [1–3] with associated
mortality and increased length of stay and cost [4]. It is
therefore a public health concern everywhere [5]. Inten-
sive care units (ICU) are increasingly involved, with more
empiric or preemptive antifungal strategies being imple-
mented in patients deemed at risk [6–8]. Many changes
have occurred over the last decade with the availability of
echinocandins, the implementation of management
guidelines [9, 10], and, at least in some centers, the
extended availability of new tools with improved diag-
nostic performances. Therefore, it is of utmost importance
to analyze whether all these (expensive) changes impac-
ted the incidence of candidemia and its associated death.
The analysis of epidemiological trends mainly relies
on hospital registers which are often focused on a specific
population [11, 12], based on a single center [13], limited
to a short period of time [14], or restricted to microbio-
logical data with limited clinical documentation [1]. We
launched in 2002 a large prospective hospital-based sur-
veillance program for patients developing candidemia in
the Paris area (France). Our expectation was that a large
population of patients over a long period of time without
selection bias related to the cause of hospitalization cause
could unravel some epidemiological shifts, in particular
by comparing populations of patients with different
underlying diseases. The goals of the study were to
describe adult patients with candidemia, to analyze trends
in incidence and mortality of candidemia in ICU versus
non-ICU hospitalized patients, and to determine risk
factors for infection by specific species and risk factors
for death.
Materials and methods
Population studied and isolates characterization
A sustainable active surveillance program on yeast fun-
gemia (YEASTS program) was implemented in October
2002 with participation of 24 short-stay university hos-
pitals in the Paris area. All blood cultures positive with
yeasts were reported by the participants, with clinical and
epidemiological data (age, recent surgery within 30 days,
cancer, hematological malignancy, transplantation, HIV
serostatus, immunosuppressive therapy, intravenous drug
addiction, invasive procedures, and recent administration
of antifungals 30 days prior to candidemia), filled on a
standardized form, on a secured website and all isolates
were sent to the French National Reference Center for
Invasive Mycoses and Antifungals (NRCMA). There,
isolates were checked for purity and identified to the
species level using carbon assimilation profiles (ID32C,
bioMe´rieux) or nucleotide sequencing as needed [15].
Because of their low proportion, C. orthopsilosis and
C. metapsilosis were included with C. parapsilosis in a
‘‘C. parapsilosis’’ complex. The current analysis concerns
the incident episodes of candidemia due to common
species (i.e., those accounting for at least 1.5 % of all
Candida spp.) recorded in adults patients (at least
15 years old) between October 2002 and September 2010.
Definitions
The date of candidemia was the day of blood sampling
(day 0). An incident case corresponded to the first episode
of positive blood culture. A recurrent episode was con-
sidered in case of isolation of the same species at least
10 days after the initial isolation or of a new species with
no time limit. To avoid autocorrelation, only incident
episodes were considered in the subsequent analysis. Both
single (one Candida species) and mixed (more than one
Candida species) infections were considered. ICU
patients were those hospitalized in ICU at the time of
sampling and we individualized candidemia episodes
occurring within 48 h of ICU stay vs. those not. First-line
antifungal therapy was analyzed only for patients for
whom the positivity of the blood culture was known
before death and was categorized into four groups:
‘‘fluconazole’’, ‘‘echinocandins’’ (aggregating all three
drugs available), ‘‘other treatments’’ (all other antifungal
drugs and drug combinations), and ‘‘no treatment’’ (no
antifungal therapy).
Statistical analysis
Incidence rates were calculated per 10,000 hospitalization
days using annual hospital activity data available since
2004 (SAE administrative data, Ministry of Health,
DREES). Univariate analysis was based on v2 or Fisher’s
exact test when needed for discrete variables. v2 test for
trends was used to determine trends over time in crude
mortality and treatments rates, and incidences of candi-
demia. In order to identify risks factors for fungemia due
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to non-albicans Candida species, a multivariate multi-
nomial regression analysis was performed using C.
albicans as reference. The year of inclusion and all
baseline variables representing preexisting conditions of
patients before fungemia were introduced into the model.
To identify risk factors associated with death in ICU
during fungemia (crude death rate), a mixed logistic
regression model was used, to account for dependency of
measurement within hospitals and adjusted on the basis of
the year of inclusion. Three models were built for the
three outcomes evaluated, i.e., overall death (at day 30),
early death (before day 8), and delayed death (between
day 8 and day 30). All covariates associated with the
outcome in univariate analysis with a p value less than
0.25 were introduced into the multivariate model to
identify covariates significantly associated with the out-
come (p \ 0.05) using a backward stepwise procedure.
Survivals were compared by the logrank test. Data were
analyzed using Stata Statistical Software (version 12.0;
College Station, TX).
Results
Characteristics of the population
During the study period, 2,507 patients had candidemia
including 95 who developed 122 recurrences. A total of
2,571 isolates were recovered during the incident episodes
related mainly to single species (2,424/2,571, 94.3 %).
Candidemia occurred in ICU in 48.1 % of the cases and
major characteristics of ICU hospitalized patients are pro-
vided in Table 1. Briefly, the majority were male (62 %),
with 518/1,206 (43.0 %) patients aged at least 65 years.
Surgery within the past 30 days was found in 48.1 % of the
patients with digestive tract and cardiovascular surgery
representing 45.2 % and 20.7 % of surgical procedures,
respectively. C. albicans was involved in 57.1 % of the
cases. In ICU, 19.8 % (96/484) of patients developed can-
didemia within 48 h following admission. Their
characteristics did not differ from those developing candi-
demia later on in terms of age, sex, allogeneic HSCT,
transplantation, hematological malignancy, arterial cathe-
ter, prior exposure to antifungals, species, and outcome.
When comparing ICU vs. non-ICU patients, the for-
mer had more frequent recent surgery and central venous
and arterial catheters, were more often preexposed to
fluconazole and treated with echinocandin, and were less
frequently infected with C. parapsilosis.
Outcome in patients with single species candidemia
ICU patients had a higher overall death rate (51 %) than
non-ICU patients (30.7 %) (p \ 0.001) and this was also
true when considering early deaths (before day 8) (Table 1).
In ICU, the survival rate of patients infected with C. par-
apsilosis was higher (logrank test p = 0.0005) and that of
patients infected with C. krusei (logrank test p = 0.0148) or
C. kefyr (logrank test p = 0.0267) lower compared to
patients infected by C. albicans (Fig. 1a). Outside ICU, the
survival rate of patients infected with C. parapsilosis was
also higher (logrank test p = 0.0018) and that of patients
infected with C. krusei (logrank test p = 0.0267) also lower
compared to patients infected by C. albicans (Fig. 1b). All
first-line antifungal treatments (fluconazole, echinocandins,
or others) were associated with a similar survival (data not
shown). The odds of death in ICU was then analyzed
according to its timing in patients with single infections
using logistic regression analysis (Table 2). Independent
risk factors for death at 30 days were age, presence of
arterial catheter, infection by C. kefyr, preexposure to
caspofungin, and lack of antifungal therapy given in those
for whom the positivity of the blood culture was known
before death and/or for whom the information about treat-
ment was recorded (p \ 0.05). In contrast, recent surgery
and infection caused by C. parapsilosis or C. glabrata were
protective. The factor associated with the highest odds of
death (11.04) was lack of initial antifungal treatment when
considering early death before day 8.
Factors associated with infection by non-albicans
Candida species or by multiple species
Since infections due to some non-albicans species are
associated with specific management recommendations, we
analyzed by multinomial regression analysis the odds of
being infected with a given species in comparison with that
of being infected with C. albicans in ICU hospitalized
patients (Table 3). The odds of infection by C. glabrata
were increased in older patients and in case of recent
exposure to fluconazole or caspofungin. The odds of
infection by C. parapsilosis were increased in patients with
recent caspofungin exposure. The odds of being infected by
C. krusei were reduced in case of recent surgery, and
increased in patients with solid tumor or solid organ trans-
plantation, and recent exposure to fluconazole or
caspofungin. The odds associated with C. tropicalis candi-
demia were the presence of hematological disorders and
recent exposure to fluconazole while the odds were reduced
in case of solid tumor. C. kefyr was associated with recent
exposure to caspofungin. Finally, odds associated with
candidemia due to multiple species were caspofungin pre-
exposure and active intravenous drug addiction.
Trends over the last decade
The incidence of candidemia in the overall population and
in ICU patients increased overtime (p = 0.01 and
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p = 0.0001, respectively) (Fig. 2). In the overall popu-
lation, C. albicans and C. glabrata were responsible for
this increase (from 0.55 in 2004 to 0.64 episodes/
10,000 days of hospitalization in 2009 (p = 0.02) and
from 0.16 in 2004 to 0.22 episodes/10,000 days of hos-
pitalization in 2009 (p = 0.01), respectively) while the
Table 1 Comparison of major characteristics according to hospitalization in intensive care unit (ICU) or not for adult patients with
incident candidemia due to common species (YEASTS program, Paris area, October 2002 to September 2010)
Conditions Hospitalization wards, n (%)
ICU (N = 1,206) Outside ICU (N = 1,301) p
Male gender 748 (62.0 %) 763 (58.7 %) 0.0844
Age categories
\45 years 219 (18.2 %) 241 (18.5 %) 0.9320
45–64 years 469 (38.9 %) 499 (38.4 %)
65–79 years 384 (31.8 %) 407 (31.3 %)
C80 years 134 (11.1 %) 154 (11.9 %)
Age mean ± SD 60 ± 17 60 ± 17 0.7482
Central venous catheter 936 (77.6 %) 919 (70.6 %) \0.0001
Arterial catheter 401 (33.3 %) 40 (3.1 %) \0.0001
Surgery within 30 days 580 (48.1 %) 389 (29.9 %) \0.0001
Digestive tracta 262/580 (45.2 %) 190/389 (48.8 %) \0.0001
Cardiovascular 120/580 (20.7 %) 20/389 (5.1 %)
Orthopedic 45/580 (7.8 %) 56/389 (14.4 %)
Urinary tract 23/580 (3.4 %) 46/389 (11.8 %)
Gynecologic 7/580 (1.2 %) 12/389 (3.1 %)
Neurosurgery 13/580 (2.4 %) 5/389 (1.3 %)
Unspecified/other sites 71/580 (12.2 %) 40/389 (10.3 %)
Multiple sitesb 39/580 (6.7 %) 20/389 (5.1 %)
Malignancy
No malignancy 828 (68.7 %) 418 (32.1 %) \0.0001
Hematological malignancy 137 (11.4 %) 285 (21.9 %)
Solid tumor 241 (20.0 %) 598 (46.0 %)
Solid organ transplantation 127 (10.5 %) 35 (2.7 %) \0.0001
HIV infection 51 (4.3 %) 47 (3.8 %) 0.4372
Allo HSCT/BMT 18 (1.5 %) 28 (2.2 %) 0.2189
Intravenous drug addiction 9 (0.75 %) 17 (1.3 %) 0.1664
Previous antifungal treatment
All 128 (10.6 %) 109 (8.4 %) 0.0559
Fluconazole 79 (6.6 %) 56 (4.3 %) 0.0127
Caspofungin 25 (2.1 %) 28 (2.2 %) 0.8904
Type of infection
Single pathogen
C. albicans 668/1169 (57.1 %) 689/1255 (54.9 %) 0.2664 0.0167
C. glabrata 234/1,169 (20.0 %) 216/1,255 (17.2 %) 0.0758
C. parapsilosis 106/1,169 (9.1 %) 173/1,255 (13.8 %) 0.0003
C. tropicalis 106/1,169 (9.1 %) 119/1,255 (9.5 %) 0.7253
C. krusei 35/1,169 (3.0 %) 35/1,255 (2.8 %) 0.7631
C. kefyr 20/1,169 (1.7 %) 23/1,255 (1.8 %) 0.8204
Multiple pathogens 37 (3.1 %) 46 (3.5 %) 0.5131
First-line treatment after diagnosisb
Fluconazole 506/914 (55.4 %) 665/1,111 (59.9 %) 0.0415 0.0013
Echinocandins 239/914 (26.2 %) 212/1,111 (19.1 %) 0.0001
Others (including combination) 115/914 (12.6 %) 148/1,111 (13.3 %) 0.6224
No treatment 54/914 (5.9 %) 86/1,111 (7.7 %) 0.1057
Death rate
Overall death at day 30 591/1,158 (51.0 %) 371/1,210 (30.7 %) \0.0001
Before day 8 367/1,151 (31.9 %) 182/1,204 (15.1 %) \0.0001
Proportional mortality day 8/day 30 367/584 (62.8 %) 182/365 (49.9 %) \0.0001
Between days 8 and 30 217/1,151 (18.9 %) 183/1,204 (15.2 %) 0.0183
Proportional mortality day 8–30/day 30 217/584 (37.2 %) 183/365 (50.1 %) \0.0001
Data are mean ± SD or n/N (%) —denominator is specified when
missing data
HSCT hematopoietic stem cell transplant, BMT bone marrow
transplantation
a Digestive tract surgery includes gastroesophageal, hepatobiliary,
colorectal, and pancreatic surgical procedures
b Denominator represents the number of patients for whom the
positivity of the blood culture was known before death and/or for
whom the information about treatment was recorded
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incidence of candidemia due to other species remained
unchanged during the study period. In ICU patients
only C. albicans incidence increased from 4.72 in 2004 to
6.31 episodes/10,000 days of hospitalization in 2009
(p = 0.005).
The major characteristics of the patients, including the
proportion of older patients, did not change between 2002
and 2010 (data not shown). Preexposure to fluconazole
did not change over time, while that of caspofungin
increased in ICU patients (p = 0.0004, data not shown).
In ICU, prescription of fluconazole decreased over time
(from 64.8 to 38.8 % in the first and last year of study,
respectively, p \ 0.0001), while that of echinocandins
increased over time (from 4.6 to 48.5 % in the first and
last year of study, respectively, p \ 0.0001).
Finally, the overall death rate increased over time in
ICU from 42.7 % in 2003 to 53.9 % in 2009 (p \ 0.003)
but remained unchanged in the overall population
(Fig. 2).
Discussion
On the basis of our analysis of a population whose charac-
teristics are similar to those found in a recent multicenter
study of septic shocks attributable to Candida spp. [16], a
significant increasing incidence of candidemia was
observed together with an increasing mortality rate in ICU.
This was observed through a large prospective multicentric
hospital-based surveillance program implemented over
almost a decade in the Paris area. Even if we are fully aware
that the epidemiology of candidemia is highly variable in
Europe and elsewhere, these trends are worrisome in the
context of expanded antifungal armamentarium, published
management guidelines, and better diagnostic tools avail-
able at least in large tertiary care centers such as those
involved in the present study [17, 18].
Of importance, similar incidence trends for candidemia
and even other invasive fungal infections were observed
recently using national registries in Europe [14, 19]. Indeed,
the epidemiology of candidemia that we described here did
not differ drastically from recently published data even if
some differences can be noted. The global proportion of
C. albicans was higher than in two recent North American
studies (56 vs. 38–42.1 %) [20, 21]. That of C. glabrata was
lower here (13.6 %) than in several recent studies reporting
at least 20 % of C. glabrata among isolates causing fun-
gemia [6, 20, 21]. C. parapsilosis ranked second in Spain,
Brazil, and Italy and third here [13, 22, 23]. Of note, relative
to ICU patients infected with C. albicans, those with
C. parapsilosis were less likely to be hospitalized in ICU,
those with C. tropicalis were more likely to have hemato-
logical disorders and less likely solid tumor, and those with
C. krusei were more likely to have a solid tumor and solid
organ transplantation but less recent surgery.
The increased incidence found here concerned two
species (C. albicans and C. glabrata) at least in the overall
population and only C. albicans in ICU. A specific increase
in C. glabrata fungemia was recently reported in the USA,
Europe, and Brazil [20, 24, 25]. We have no explanation for
the increased incidence of C. albicans. We know that species
involved can largely be influenced by ecosystems and local
management of the patients at risk. In a recent study, 15 %
of the patients were preexposed to antifungal, including
fluconazole in 64 % and echinocandins in 15 % [7], while in
another one, preexposure concerned up to 43.4 % of the
patients [21] especially (more than 67 % of the cases) those
with breakthrough episodes [12]. Here, preexposure con-
cerned 10.6 % of patients hospitalized in ICU. Preexposure
to fluconazole did not change over time, while that of
caspofungin increased in ICU. We and others have previ-
ously evidenced the impact of prolonged prior fluconazole
exposure on the distribution of Candida species [15, 24, 26].
Interestingly, in the current multinomial analysis performed
in ICU patients with C. albicans as the reference, preexpo-
sure to fluconazole was an independent factor of infection
Fig. 1 Kaplan–Meier curves illustrating survival rate after candi-
demia according to the species involved in case of single infection
in ICU a and outside ICU b. YEASTS program, Paris area (October
2002 to September 2010)
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with C. krusei, C. tropicalis, or C. glabrata, whereas pre-
exposure to caspofungin was an independent factor of
infection with C. parapsilosis, C. krusei, C. kefyr, C. glab-
rata, and mixed infections, thereby emphasizing the broader
than expected ecological impact of echinocandin exposure
[15, 27, 28]. It should also be remembered that in addition to
the emergence of potentially more virulent Candida species
induced by echinocandin exposure such as C. krusei and
C. kefyr found here, the emergence of echinocandin resis-
tance among usually susceptible Candida species is also
worrisome [29, 30].
Our large database allowed us to focus on trends in death
and look for explanations of the increased death rate over time
in the overall population and in ICU. The first explanation
could be the species involved. Here and in other studies [3, 13,
21, 31], C. parapsilosis and C. krusei/C. kefyr were associated
with the lowest and highest death rates, respectively, while
others found an increased death rate among patients with
C. tropicalis or C. glabrata fungemia [32, 33]. However, the
mortality trends cannot be explained by the evolving distri-
bution of C. parapsilosis or C. krusei/C. kefyr. Another
explanation might have been an increased proportion of
elderly patients over time in ICU. However, it remained
stable yet high (31.8 and 11.1 % of episodes occurred in
patients aged at least 65 years and at least 80 years, respec-
tively) as already noted by others with the highest incidence
rates of candidemia in adults over 65 [7]. The death rate is also
known to depend on underlying diseases or settings, as found
here in ICU patients (51 %) and as already reported [14].
However, although mortality remained stable for the overall
population, the most worrying finding is its increase in ICU.
Several recent studies reported changes in the case-mix of
critically ill patients. Nationwide trends of severe sepsis in the
USA showed that from 2000 to 2007, more patients had at
least three organ system failures [34]. In an Australian tertiary
ICU, there was a significant increase in severity of illness and
Charlson comorbidity index of the patients over a 16-year
study period [35]. Finally, although we did not capture this
information during our large prospective surveillance pro-
gram, unpublished data from ICUs which participated in the
present study indicate that the simplified acute physiology
score II score and the percentage of mechanically ventilated
patients increased from 37, 42 to 44, and from 41, 49, to 60 %
in 2000, 2005, and 2010, respectively [CubRea Network
(‘‘Colle`ge des Utilisateurs des Bases de Donne´es en Re´ani-
mation’’), Ile de France; Biostatistique et Informatique
Me´dicale, Hoˆpital Ambroise Pare´, Boulogne, France].
However, a recent study showed an average annual increase
in the incidence of severe sepsis of 13 % between 2004 and
2009 while in-hospital death decreased from 35 to 25.6 %
across the 6-year period [36]. In addition, a recent meta-
analysis of 36 multicenter severe sepsis trials, with a total of
14,418 participants, found a decreasing mortality of 3.0 %
annually (95 % CI, 0.8–5.0 %; p = 0.009), decreasing from
46.9 % during years 1991–1995 to 29 % during years
2006–2009 [37]. Thus, it can be speculated that more ICU
Table 2 Risk factors for death in adult patients hospitalized in intensive care unit (ICU) with incident candidemia due to a single isolate
(logistic regression), YEASTS program, Paris area, October 2002 to September 2010
Death before day 30 Death before day 8 Death between day 8 and day 30
Adj. OR 95 % CI p Adj. OR 95 % CI p Adj. OR 95 % CI p
Male gender 0.71 0.51–0.99 0.043
Age categories
\45 years 1 0.0001 1 0.0003
45–64 years 1.66 1.09–2.53 2.32 1.38–3.89
65–79 years 2.49 1.60–3.56 3.19 1.88–5.43
C80 years 3.09 1.73–5.49 2.91 1.45–5.83
Arterial catheter 1.39 1.01–1.92 0.0430 1.47 1.02–2.11 0.0371
Surgery within 30 days 0.62 0.46–0.84 0.0017 0.54 0.39–0.76 0.0004
Species
C. albicans 1 0.0013 1 0.0031
C. grabrata 0.65 0.43–0.98 0.58 0.34–1.02
C. parapsilosis 0.43 0.25–0.76 0.18 0.06–0.52
C. tropicalis 0.99 0.61–1.63 1.00 0.53–1.86
C. krusei 1.78 0.71–4.47 1.55 0.57–4.23
C. kefyr 3.88 1.14–13.26 2.79 0.84–9.21
Preexposure to caspofungin 3.83 1.29–11.35 0.0153 3.54 1.09–11.53 0.0357
First-line treatment
Fluconazole 1 0.0003 1 \0.0001
Echinocandin 1.23 0.85–1.80 0.98 0.59–1.61
Other treatment 1.11 0.69–1.79 0.81 0.42–1.56
No treatment 4.34 2.23–8.45 11.04 5.72–21.30
Variables included in full model (with p \ 0.25 in univariate
analysis of death): male gender, age, arterial catheter, surgery
within 30 days, malignancy, transplantation, preexposure to
caspofungin, species, first-line treatment
Adj. OR adjusted odds ratio for hospital and year, 95 % CI odds
ratio 95 % confidence interval, HSCT hematopoietic stem cell
transplant, BMT bone marrow transplantation
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Table 3 Risk factors for fungemia in intensive care unit (N = 1,206) due to C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. kefyr, or multiple species in
reference to fungemia due to C. albicans
C. glabrata C. parapsilosis C. tropicalis
Adj. ORa 95 % ICb p Adj. ORa 95 % ICb p Adj. ORa 95 % ICb p
Male gender 1.07 0.78–1.48 0.660 1.10 0.71–1.69 0.683 1.27 0.81–1.99 0.294
Age less than 45 years 1 1 1
Between 45–64 years 1.60 0.96–2.67 0.074 0.77 0.45–1.32 0.340 1.09 0.59–2.02 0.788
Between 65–79 years 2.02 1.19–3.43 0.009 0.55 0.30–1.01 0.055 1.54 0.81–2.90 0.187
80 years and more 2.68 1.43–5.01 0.002 0.73 0.33–1.60 0.428 0.95 0.38–2.38 0.916
Central venous catheter 1.00 0.69–1.45 0.988 1.36 0.79–2.32 0.263 1.25 0.73–2.14 0.413
Arterial catheter 0.90 0.64–1.27 0.545 0.96 0.60–1.53 0.856 0.91 0.56–1.49 0.710
Surgery within 30 days 1.09 0.79–1.52 0.596 1.27 0.82–1.98 0.291 1.01 0.64–1.61 0.957
No malignancy 1 1 1
Hematological malignancy 1.08 0.63–1.86 0.771 0.57 0.25–2.29 0.179 2.22 1.24–3.99 0.007
Solid tumor 1.09 0.74–1.60 0.658 0.59 0.32–1.10 0.096 0.49 0.25–0.97 0.042
Solid organ transplantation 0.74 0.42–1.31 0.305 0.76 0.38–1.51 0.428 0.75 0.35–1.62 0.469
HIV infection 0.51 0.19–1.39 0.188 1.08 0.39–3.03 0.879 0.92 0.34–2.45 0.861
Intravenous drug addiction 2.01 0.34–11.90 0.444 NC NC
Caspofungin pre-exposure 16.63 3.51–78.76 \0.001 17.86 3.27–97.46 0.001 3.42 0.29–39.68 0.326
Fluconazole pre-exposure 4.09 2.26–7.41 \0.001 1.02 0.33–3.09 0.976 3.48 1.63–7.46 0.001
C. krusei C. kefyr ‘‘Mixed’’ infections
Adj. ORa 95 % ICb p Adj. ORa 95 % ICb p Adj. ORa 95 % ICb p
Male gender 1.65 0.74–3.71 0.222 0.74 0.29–1.88 0.532 1.06 0.52–2.19 0.865
Age less than 45 years 1 1 1
Between 45–64 years 0.73 0.28–1.90 0.513 1.90 0.39–9.38 0.429 1.27 0.39–4.07 0.691
Between 65–79 years 0.88 0.30–2.60 0.811 2.97 0.59–14.86 0.184 1.46 0.43–5.00 0.543
80 years and more 1.43 0.33–6.23 0.632 1.02 0.09–11.91 0.990 4.19 1.15–15.31 0.030
Central venous catheter 0.92 0.39–2.16 0.849 0.80 0.27–2.33 0.677 1.47 0.58–3.70 0.412
Arterial catheter 0.51 0.21–1.24 0.136 1.45 0.52–4.01 0.480 0.92 0.44–1.95 0.832
Surgery within 30 days 0.40 0.17–0.92 0.032 0.58 0.21–1.59 0.291 1.28 0.60–2.71 0.528
No malignancy 1 1 1
Hematological malignancy 2.07 0.72–5.93 0.177 2.06 0.57–7.40 0.270 1.23 0.33–4.58 0.757
Solid tumor 3.11 1.29–7.49 0.012 1.42 0.47–4.29 0.536 1.68 0.74–3.83 0.215
Solid organ transplantation 3.06 1.13–8.31 0.028 0.54 0.07–4.45 0.569 1.45 0.45–4.64 0.530
HIV infection 1.72 0.42–7.04 0.452 NC 1.19 0.21–6.84 0.848
Intravenous drug addiction NC NC 13.71 1.77–106.28 0.012
Caspofungin pre-exposure 51.86 8.44–318.52 \0.001 16.93 1.29–221.63 0.031 12.51 1.05–149.70 0.046
Fluconazole pre-exposure 6.43 2.32–17.83 \0.001 4.33 0.88–21.24 0.071 0.77 0.10–6.02 0.800
Multivariate multinomial regression analysis, YEASTS program, Paris area, October 2002 to September 2010
Adj. OR adjusted odds ratio for year, 95 % CI odds ratio 95 % confidence interval
Fig. 2 Trends in the incidence of candidemia (a) and in death rate at day 30 (b). YEASTS program, Paris area, France. The parameters
are analyzed for all patients (blue line) and patients hospitalized in ICU (red line)
1309
patients now survive from bacterial sepsis and could be fur-
ther exposed to life-threatening ICU-acquired candidemia.
The lack of overall diminution and a fortiori the increased
death rate found in ICU patients are shocking knowing that
new antifungals became available and that several guidelines
for the management of candidemia were published during the
same period. Among ICU patients, 55.4 % were treated with
fluconazole and 26.2 % with an echinocandin, a percentage
close to what was reported recently in the USA [7] even if
more echinocandins were prescribed in one study [31]. Other
studies found that receiving an antifungal was an independent
factor decreasing both early and late death [22] and that
echinocandins as first-line therapy reduced the death rate
[38]. In the present study, outcome did not change according
to initial antifungal therapy, and only lack of initial antifungal
therapy impacted both overall and early deaths. Moreover,
preexposure to caspofungin had a negative impact on the
outcome. Although numerous other factors not captured here
may have influenced the outcome, such as the delayed initi-
ation of adequate antifungal therapy [8, 39, 40], although
controversial [16], lack of consideration of antifungal dosing
issues [40–42], and inadequate source control as recently
emphasized [16], both the strong ecological impact and
potentially its deleterious effect on outcome emphasize the
need for not only triazole but also echinocandin stewardship
in our hospitals.
In conclusion we observed an increase in the incidence
of candidemia and its death rate in ICU. The causes of
these worrisome trends merit further studies.
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Appendix
The following investigators participated in the YEASTS
program of the French Mycosis Study Group: collection
of data in each participating center: C. Bouges-Michel
(hoˆpital Avicenne, Bobigny), I. Poilane (hoˆpital Jean
Verdier, Bondy), J. Dunan (hoˆpital Ambroise Pare´, Bou-
logne), G. Galeazzi (hoˆpital Louis Mourier, Colombes),
A. Alanio, F. Foulet (hoˆpital Henri Mondor, Cre´teil), N.
Fauchet (Centre Intercommunal, Cre´teil), E. Forget
(hoˆpital Beaujon, Clichy), C. Lawrence (hoˆpital Raymond
Poincare´, Garches), A. Angoulvant, C. Bonnal, C. Hen-
nequin, F. Botterel (hoˆpital du Kremlin Biceˆtre, Kremlin-
Biceˆtre), O. Eloy (Centre Hospitalier, Le Chesnay), M.-F.
David, N. Khassis, L. Milhaila (hoˆpital Paul Brousse,
Villejuif), E. Chachaty (Institut Gustave Roussy, Ville-
juif), and in Paris: C. Chochillon (hoˆpital Bichat), F.
Lesle, A. Paugam, M.-T. Baixench (hoˆpital Cochin),
M.-C. Escande (Institut Curie), M. Cornet (Hoˆtel Dieu),
M.-E. Bougnoux, Y. Sterckers, S. Challier (hoˆpital
Necker), E. Dannaoui, V. Lavarde (hoˆpital Europe´en
Georges Pompidou), A. Datry, B. L. Mimouni, S. Brun,
A. Fekkar (hoˆpital de la Pitie´-Salpe´trie`re), J. Guitard, J.-
L. Poirot (hoˆpital Saint Antoine), C. Lacroix (hoˆpital
Saint Louis, Fernand Widal et Lariboisie`re), D. Moissenet
(hoˆpital Trousseau), M. Develoux (hoˆpital Tenon), P.
Mariani, S. Bonacorsi (hoˆpital Robert Debre´). Technical
analysis of the isolates at the National Reference Center
for Invasive Mycoses and Antifungals: Marie Desnos-
Ollivier, Dea Garcia-Hermoso, Damien Hoinard, Dor-
othe´e Raoux.
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